TCM
AXDX

Timpani Capital Management’s Accelerate Diagnostics AXDX Stock Holding History

Timpani Capital Management’s Portfolio AXDX Stock Details AXDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-9,258
Closed -$2.53M – 105
2017
Q2 		$2.53M Buy
+9,258
New +$2.51M 0.94% 49

Other funds holding AXDX

OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $214M AUM 185.33% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CC
Cannell & Co New York $3.15B AUM 30.62% 1-Year Est. Return
PC
Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return
MGM
Miura Global Management New York $25.2M AUM 60.6% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $38.4B AUM 25.71% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return

Timpani Capital Management's AXDX Position: Q3 2017 in Review

Timpani Capital Management sold out of Accelerate Diagnostics (AXDX) in Q3 2017, closing a stake of 9,258 shares — an estimated $2.53M sold.

Timpani Capital Management first reported a position in AXDX in Q2 2017 and held it in 1 quarter. The position peaked at $2.53M in Q2 2017. 118 funds tracked by Wall St. Rank hold AXDX as of Q3 2017.

  • Timpani Capital Management reported no remaining Accelerate Diagnostics position as of Q3 2017 after selling out during the quarter.
  • Timpani Capital Management sold 9,258 Accelerate Diagnostics shares in Q3 2017, an estimated $2.53M.
  • Timpani Capital Management first reported a position in Accelerate Diagnostics in Q2 2017 and held it in 1 quarter.
  • Timpani Capital Management's Accelerate Diagnostics position peaked at $2.53M in Q2 2017.
  • 118 funds tracked by Wall St. Rank held Accelerate Diagnostics as of Q3 2017.

Based on Timpani Capital Management's 13F filing for Q3 2017, filed 13 Nov 2017.